⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APVO News
Aptevo Therapeutics Inc
Form 8-K
sec.gov
APVO
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
accessnewswire.com
APVO
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
accessnewswire.com
APVO
Form 8-K
sec.gov
APVO